Literature DB >> 15364454

Recombinant vesicular stomatitis (Indiana) virus expressing New Jersey and Indiana glycoproteins induces neutralizing antibodies to each serotype in swine, a natural host.

Isidoro Martinez1, Jose C Barrera, Luis L Rodriguez, Gail W Wertz.   

Abstract

Vesicular stomatitis virus (VSV) is the most common cause of vesicular disease outbreaks in livestock throughout the Western Hemisphere. Two major serotypes, Indiana and New Jersey, cause epidemic disease in pigs, cattle, and horses. We generated recombinant viruses derived from the Indiana serotype genome that were engineered to contain and express: (1) a single copy of the glycoprotein gene from the Indiana serotype (VSIV-GI); (2) a single copy of the glycoprotein gene from the New Jersey serotype (VSIV-GNJ); or (3) two copies of the glycoprotein gene, one from each of the two major VSV serotypes (VSIV-GNJGI) [Martinez I, Rodriguez LL, Jimenez C, Pauszek SJ, Wertz GW. Vesicular stomatitis virus glycoprotein is a determinant of pathogenesis in swine, a natural host. J Virol 2003;77(14):8039-47]. These recombinant viruses and a highly pathogenic New Jersey field isolate (VSNJV), from which the GNJ gene was derived, were inoculated into swine, a natural host, and the induction of neutralizing antibodies to both serotypes was analyzed. The neutralizing antibody response induced by VSIV-GI, VSIV-GNJ and VSNJV was serotype-specific, according to the glycoprotein expressed. VSIV-GNJGI expressed both glycoproteins stably through multiple rounds of replication in swine and induced neutralizing antibodies against both VSV serotypes, with a dominance of the Indiana serotype in the serological response. Pigs immunized with VSIV-GI or VSIV-GNJ were protected against homologous high dose virus challenge. Pigs inoculated with VSIV-GNJGI were protected against challenge with VSIV-GI but three of four animals developed lesions after challenge with the highly pathogenic New Jersey field isolate.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15364454     DOI: 10.1016/j.vaccine.2004.03.065

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

Review 1.  Viruses as anticancer drugs.

Authors:  Stephen J Russell; Kah-Whye Peng
Journal:  Trends Pharmacol Sci       Date:  2007-06-18       Impact factor: 14.819

2.  Oncolytic Recombinant Vesicular Stomatitis Virus (VSV) Is Nonpathogenic and Nontransmissible in Pigs, a Natural Host of VSV.

Authors:  Lauro Velazquez-Salinas; Shruthi Naik; Steven J Pauszek; Kah-Whye Peng; Stephen J Russell; Luis L Rodriguez
Journal:  Hum Gene Ther Clin Dev       Date:  2017-06       Impact factor: 5.032

3.  Enzyme-linked immunosorbent assay using glycoprotein and monoclonal antibody for detecting antibodies to vesicular stomatitis virus serotype New Jersey.

Authors:  Hyang-Sim Lee; Eun-Jeong Heo; Hye-Young Jeoung; Hyo-Rim Ko; Chang-Hee Kweon; Hee-Jeong Youn; Young-Joon Ko
Journal:  Clin Vaccine Immunol       Date:  2009-03-11

4.  Evaluation of attenuated VSVs with mutated M or/and G proteins as vaccine vectors.

Authors:  Xinkui Fang; Shikuan Zhang; Xiaodong Sun; Jinjin Li; Tao Sun
Journal:  Vaccine       Date:  2012-01-02       Impact factor: 3.641

5.  Recombinant adenovirus expressing vesicular stomatitis virus G proteins induce both humoral and cell-mediated immune responses in mice and goats.

Authors:  Xiaojuan Xue; Zhaorong Yu; Hongyan Jin; Lin Liang; Jiayang Li; Xiaolu Li; Yong Wang; Shangjin Cui; Gang Li
Journal:  BMC Vet Res       Date:  2021-01-18       Impact factor: 2.741

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.